Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Archives of Neurology

• Publication date

  2005-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/ARCHNEUR.62.4.601PMID 15824260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gender differences in Parkinson’s disease

  2006cited by this paper
• Association of Seven Polymorphisms of the D2 Dopamine Receptor Gene with Brain Receptor-Binding Characteristics

  2004cited by this paper
• Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease

  2002cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000cited by this paper
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients

  1999cited by this paper
• Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.

  1999cited by this paper
• Risk factors for levodopa-induced dyskinesias in Parkinson’s disease

  1999cited by this paper
• Gender differences in Parkinson's disease.

  1998cited by this paper
• Motor Complications of Chronic Levodopa Therapy in Parkinson's Disease

  1997cited by this paper
• Short‐term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease

  1997cited by this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

  1996cited by this paper
• Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients

  1996cited by this paper
• Evolution of haplotypes at the DRD2 locus.

  1995cited by this paper
• Age at onset: the major determinant of outcome in Parkinson's disease

  1995cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale

  1987cited by this paper

• Sex and gender-related differences in neurological diseases: current challenges and recommendations for clinical practice

  2026cites this paper
• Sexual Dimorphism in Levodopa‐Induced Dyskinesia Following Parkinson's Disease: Uncharted Territory

  2025cites this paper
• Sex differences in neurological disorders: Insights from ischemic stroke, Parkinson's disease, and multiple sclerosis.

  2025cites this paper
• Advancing age and sex modulate antidyskinetic efficacy of striatal CaV1.3 gene therapy in a rat model of Parkinson's disease.

  2025cites this paper
• Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases.

  2025cites this paper
• Gender Is the Main Predictor of Wearing‐Off and Dyskinesia in Levodopa‐Naïve Patients with Parkinson's Disease

  2025cites this paper
• Levodopa‐Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5‐Year Follow‐Up Study

  2024cites this paper
• Motor Complications in Parkinson's Disease: Results from 3343 Patients Followed for up to 12 Years

  2024cites this paper
• Critical evaluation of the current landscape of pharmacogenomics in Parkinson's disease - What is missing? A systematic review.

  2024cites this paper
• An Artificial Neural Network Predicts Gender Differences of Motor and Non-Motor Symptoms of Patients with Advanced Parkinson’s Disease under Levodopa–Carbidopa Intestinal Gel

  2024cites this paper
• Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia

  2024cites this paper
• Preservation of Intrinsically Photosensitive Retinal Ganglion Cells (ipRGCs) in Late Adult Mice: Implications as a Potential Biomarker for Early Onset Ocular Degenerative Diseases

  2024cites this paper
• Sex Differences in Parkinson’s Disease: A Narrative Review

  2024cites this paper
• Unraveling sex differences in Parkinson's disease through explainable machine learning.

  2024cites this paper
• Gender gap in deep brain stimulation for Parkinson’s disease: preliminary results of a retrospective study

  2024cites this paper
• Sex and gender differences in Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis: a narrative review.

  2023cites this paper
• Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions

  2023cites this paper
• Activation of mGlu2/3 receptors in the striatum alleviates L-DOPA-induced dyskinesia and inhibits abnormal postsynaptic molecular expression.

  2023cites this paper
• Artificial neural network predicts sex differences of patients with advanced Parkinsons disease under Levodopa-Carbidopa Intestinal gel

  2023cites this paper
• Systems level analysis of sex-dependent gene expression changes in Parkinson’s disease

  2023cites this paper
• Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia

  2023influential citation
• An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease

  2023cites this paper
• Evaluation of risk factors for impulse control disorder in Parkinson’s disease in northern China

  2023cites this paper
• Sex and Gender Differences in Parkinson's Disease.

  2023cites this paper
• Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson's Disease

  2022cites this paper
• Gender differences in motor and non-motor symptoms in early Parkinson disease

  2022cites this paper
• Bias Investigation in Artificial Intelligence Systems for Early Detection of Parkinson’s Disease: A Narrative Review

  2022cites this paper
• A Computerized Analysis with Machine Learning Techniques for the Diagnosis of Parkinson’s Disease: Past Studies and Future Perspectives

  2022cites this paper
• Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s Disease

  2022cites this paper
• Association of Catechol-O-Methyltransferase Gene Polymorphisms and Haplotypes in the Levodopa-Induced Adverse Events in Subjects with Parkinson’s Disease

  2022cites this paper
• Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling

  2022cites this paper
• Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias.

  2022cites this paper
• Dyskinesia and Parkinson’s disease: animal model, drug targets, and agents in preclinical testing

  2022cites this paper
• Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies

  2022cites this paper
• Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review

  2022cites this paper
• Prediction of Parkinson's Disorder: A Machine Learning Approach

  2022cites this paper
• Sex modulates the outcome of subthalamic nucleus deep brain stimulation in patients with Parkinson’s disease

  2022cites this paper
• Parkinson's disease: Present and future of cell therapy

  2022cites this paper
• Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson’s disease: a systematic review and meta-analysis

  2022cites this paper
• Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

  2022cites this paper
• Sex and gender differences in movement disorders: Parkinson's disease, essential tremor, dystonia and chorea.

  2022cites this paper
• A Systematic Review of Parkinson’s Disease Pharmacogenomics: Is There Time for Translation into the Clinics?

  2021cites this paper
• Polymorphisms of Dopamine Receptor Genes and Parkinson’s Disease: Clinical Relevance and Future Perspectives

  2021cites this paper
• Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson’s Disease

  2021cites this paper
• Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view.

  2021cites this paper
• Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

  2021cites this paper
• Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease

  2021cites this paper
• Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.

  2021cites this paper
• Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia

  2021cites this paper
• New Insights into Pathogenesis of L-DOPA-Induced Dyskinesia.

  2021cites this paper
• Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.

  2020cites this paper
• The role of pharmacogenomics in personalization of the Parkinson's disease treatment.

  2020cites this paper
• Sexual Dimorphism in Drug Metabolism and Pharmacokinetics.

  2020cites this paper
• Does gender differences have a role in determining sleep quality in Parkinson’s disease?

  2020cites this paper
• Sexually dimorphic responses to MPTP found in microglia, inflammation and gut microbiota in a progressive monkey model of Parkinson’s disease

  2020cites this paper
• Analysis of factors associated with brittle response in patients with Parkinson’s disease

  2020cites this paper
• Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease

  2020cites this paper
• Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease

  2020cites this paper
• Sex differences in movement disorders.

  2020cites this paper
• Current clinical approaches in neurodegenerative diseases

  2020cites this paper
• Sex differences in movement disorders

  2020cites this paper
• Sex differences in Parkinson's disease: A transcranial magnetic stimulation study

  2019cites this paper
• Improvement of Deep Brain Stimulation in Dyskinesia in Parkinson's Disease: A Meta-Analysis

  2019cites this paper
• Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease

  2019cites this paper
• Vasomotor changes in the striatum associated with levodopa-induced dyskinesia in parkinsonian rat model

  2019cites this paper
• Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis.

  2019cites this paper
• Predictors of motor complications in early Parkinson's disease: A prospective cohort study

  2019cites this paper
• Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells

  2019cites this paper
• DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.

  2019cites this paper
• Age and time course of long-term motor and nonmotor complications in Parkinson disease

  2018cites this paper
• Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

  2018cites this paper
• Effects of Genetic Variability in Dopaminergic Pathway on Treatment Response in Parkinson’s Disease

  2018cites this paper
• NON-MOTOR SYMPTOMS ARE MORE FREQUENT IN WOMEN THAN IN MEN WITH PARKINSON’S DISEASE CZĘSTSZE WYSTĘPOWANIE OBJAWÓW POZARUCHOWYCH U KOBIET NIŻ

  2018cites this paper
• Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort

  2018cites this paper
• Deep Brain Stimulation of the Subthalamic Nucleus Parameter Optimization for Vowel Acoustics and Speech Intelligibility in Parkinson's Disease.

  2018cites this paper
• Pharmacogenetics and levodopa induced motor complications

  2018cites this paper
• Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies

  2018cites this paper
• Levodopa-induced dyskinesia: clinical features, incidence, and risk factors

  2018cites this paper
• Toe dystonia in Parkinson's disease: Impact of subthalamic nucleus deep brain stimulation.

  2018cites this paper
• Improving pharmacological treatment in brain and mental health disorders: the need for gender and sex analyses.

  2018cites this paper
• Analysis of Motor Complications in Parkinson’s Disease Phenotypes

  2018cites this paper
• The role of gender in Parkinson’s disease

  2017cites this paper
• CLINICAL FEATURES OF LEVODOPA-INDUCED DYSKINESIA IN PATIENTS WITH PARKINSON’S DISEASE

  2017influential citation
• Association of the DRD2 CAn-STR and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists.

  2017cites this paper
• The relevance of gender in Parkinson’s disease: a review

  2017cites this paper
• Comparison of Parkinson’s Disease Features in Males and Females

  2017cites this paper
• Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa

  2017cites this paper
• A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson’s disease

  2017cites this paper
• Pharmacogenetics of Parkinson's Disease in Clinical Practice

  2017cites this paper
• Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management

  2017cites this paper
• Personalized medicine in Parkinson's disease: Time to be precise

  2017cites this paper
• Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk?

  2017cites this paper
• Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.

  2017cites this paper
• Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease

  2017cites this paper
• A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson’s Disease

  2017cites this paper
• Risk factors for levodopa-induced dyskinesia in Parkinson’s disease patients

  2017cites this paper
• Relationship Between Voice and Motor Disabilities of Parkinson's Disease.

  2016cites this paper
• Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.

  2016cites this paper
• How close are we to individualized medicine for Parkinson’s disease?

  2016cites this paper
• Risk and course of motor complications in a population-based incident Parkinson's disease cohort.

  2016cites this paper